NCT03661268 is a NA clinical trial of fluid chanllenge in Septic Shock, sponsored by Chengdu Fifth People's Hospital.

Who is sponsoring NCT03661268?

NCT03661268 is sponsored by Chengdu Fifth People's Hospital.

What drugs are being tested in NCT03661268?

Interventions in NCT03661268: fluid chanllenge.

What condition does NCT03661268 study?

NCT03661268 studies Septic Shock.

Is NCT03661268 still recruiting?

NCT03661268 is currently status unknown. Last updated 28 January 2021.

Last reviewed 2021-01-28 · How we verify

NCT03661268

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Rapid Fluid Challenge Under Pulmonary Artery Catheter Monitoring on Physiological Indexes of Patients With Septic Shock

Status unknown NA Last updated 28 January 2021

What this trial tests

NA trial testing fluid chanllenge in Septic Shock in 100 participants. Status unknown.

Timeline

1 October 2018

Primary endpoint
28 February 2021

30 September 2021

Quick facts

Lead sponsor	Chengdu Fifth People's Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 October 2018
Primary completion	28 February 2021
Estimated completion	30 September 2021
Sites	1 location across China

Drugs / interventions tested

fluid chanllenge

Conditions studied

Septic Shock — all drugs for Septic Shock →

Sponsor

Chengdu Fifth People's Hospital

Who can join

Adults 18 to 75, any sex, with Septic Shock. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Fluid challenge is often carried out in septic shock patients. Its responsiveness usually requires invasive monitoring. The pulmonary artery catheter(PAC) is the most effective means of monitoring.To use non-invasive methods is very tempting. Investigators hypothesize that venous-to-arterial carbon dioxide difference,venous-to-arterial carbon oxygen difference, central venous-arterial carbon dioxide to arterial-venous oxygen content ratio and Central Venous SO2 variations provides feasible estimation on fluid responsiveness in septic shock patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Septic Shock

Currently open trials in the same condition.

NCT07179276 — Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock · NA · recruiting
NCT07383103 — Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock · Phase 4 · recruiting
NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
NCT07264543 — Early Methylene Blue in the Microhemodynamics of Septic Patients · Phase 2, PHASE3 · recruiting
NCT04855786 — External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03661268 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chengdu Fifth People's Hospital
Last refreshed: 28 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03661268.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing